The present invention relates generally to the field of diagnostic methods. More specifically, the present invention pertains to certain 18F-labelled barbiturate compounds of the following formula (collectively referred to herein as "18F-fluorinated barbiturate compounds" and "18FBAR compounds") that bind to metals, for example, metals associated with protein aggregates, and as such are useful as imaging agents for positron emission imaging (e.g., positron emission tomography (PET) imaging) used in the diagnosis and monitoring of conditions involving these aggregates, including Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD). These compounds also bind strongly to GABAA receptors and hence are also useful as imaging agents for positron emission tomography (PET) imaging used in the diagnosis, monitoring and study of diseases involving dis-regulation of these receptors, including epilepsy, schizophrenia, and mood disorders (e.g., anxiety).
本发明通常涉及诊断方法领域。更具体地说,本发明涉及以下
化学式的某些18F标记的
巴比妥化合物(以下统称为“18F
氟代
巴比妥化合物”和“18F
BAR化合物”),这些化合物结合到
金属,例如与蛋白聚集物相关的
金属,并因此可用作正电子发射成像(例如正电子发射断层扫描(PET)成像)的成像剂,用于诊断和监测涉及这些聚集物的疾病,包括阿尔茨海默病(AD)、帕
金森病(PD)和亨廷顿病(
HD)。这些化合物还强烈结合到
GABAA受体,因此也可用作正电子发射断层扫描(PET)成像的成像剂,用于诊断、监测和研究涉及这些受体失调的疾病,包括癫痫、精神分裂症和情绪障碍(例如焦虑)。